Back to top
more

iShares U.S. Pharmaceuticals ETF: (IHE)

(Delayed Data from NYSE) As of Feb 27, 2026 04:00 PM ET

$91.47 USD

91.465
133,497

+0.74 (0.81%)

Volume: 133,497

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

2 - Buy of 5   2      

After-Market: $91.84 +0.38 (0.41 %) 7:58 PM ET

Zacks News

Sweta Killa headshot

JNJ Beats on Q2 Earnings, Ups View: ETFs to Buy

The company recorded 164 million in COVID-19 vaccine sales in the second quarter, up 64% from the first, and aims to fetch $2.5 billion in sales by the end of the year.

Sweta Killa headshot

5 Sector ETFs That Survived Last Week's Turmoil

We have highlighted five sector ETFs that performed well last week and survived the broad market rout.

Sweta Killa headshot

Pharma ETFs in Focus Post Q1 Earnings

The slew of Q1 results have led to mixed trading in pharma ETFs over the past month.

Sweta Killa headshot

Healthcare ETFs in Focus Post JNJ's Q1 Earnings Results

Johnson & Johnson (JNJ) continued its long streak of earnings beat and outpaced revenue estimates. However, the company tightened its full-year guidance.

Sweta Jaiswal, FRM headshot

Will J&J ETFs Suffer on Latest COVID-19 Vaccine Updates?

Let's take a look at some ETFs that can see adverse impacts as Johnson & Johnson's coronavirus vaccine sees a setback amid the worsening pandemic conditions.

Sweta Jaiswal, FRM headshot

ETFs to Shine on Pfizer's Impressive COVID-19 Vaccine Update

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.

Sweta Jaiswal, FRM headshot

J&J ETFs to Shine Bright as FDA Grants EUA for Coronavirus Vaccine

Johnson & Johnson's receipt of EUA for its single-shot COVID-19 vaccine will strengthen the U.S. government's position in the fight against the pandemic and benefit ETFs with high exposure to the pharmaceutical giant.